Search results
Pfizer Inc. Just Beat EPS By 61%: Here's What Analysts Think Will Happen Next
Simply Wall St. via Yahoo Finance· 10 hours agoPfizer Inc. (NYSE:PFE) just released its first-quarter report and things are looking bullish. It was...
Pfizer agrees to settle over 10K lawsuits linking Zantac to cancer
New York Post· 3 days agoPfizer has agreed to settle more than 10,000 lawsuits which alleged that the company failed to warn...
Here's How to Play Pfizer (PFE) Stock Ahead of Q1 Earnings
Zacks via Yahoo Finance· 2 weeks agoPfizer (PFE) expects its operational revenues to improve, driven by its in-line products like...
Pfizer Inc's Dividend Analysis
GuruFocus.com via Yahoo Finance· 4 days agoPfizer Inc (NYSE:PFE) recently announced a dividend of $0.42 per share, payable on 2024-06-14, with the ex-dividend date set for 2024-05-09. As investors...
A Struggling Pfizer Looks for Help From a Wall Streeter
Barrons.com· 1 day agoAs the big drugmaker tries to turn its fortunes around by focusing on oncology, it has turned to a...
Pharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab
Zacks via Yahoo Finance· 1 day agoPfizer (PFE) reports the death of a participant in a mid-stage study of its Duchenne drug. An FDA...
Pfizer agrees to settle 10K Zantac lawsuits, as GSK trial links heartburn drug to cancer
BenefitsPRO· 2 days agoPfizer has agreed to settle more than 10,000 cases accusing it of hiding the cancer risks of its...
Is Pfizer Stock Fully Valued At $28?
Forbes· 5 days agoPfizer (NYSE: PFE) reported its Q1 results last week, with revenues and earnings beating the street estimates.
Top Stock Reports for Amazon.com, Visa & Pfizer
Zacks via Yahoo Finance· 1 day agoToday's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Visa Inc. (V) and Pfizer Inc. (PFE). These...
Decoding Pfizer Inc (PFE): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 2 days agoStrengths highlight Pfizer's robust product portfolio and global market presence. Weaknesses underscore the challenges in revenue fluctuations and patent...